FindTrial
Sign In

Lanraplenib

DRUG4 trials

Sponsors

Gilead Sciences, Kronos Bio

Conditions

Acute Myeloid LeukemiaCutaneous Lupus ErythematosusLupus Membranous NephropathyRefractory Acute Myeloid LeukemiaRelapsed Acute Myeloid LeukemiaSjogren's Syndrome

Phase 1

A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)
TerminatedNCT05028751
Kronos BioAcute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
Start: 2022-08-05End: 2024-04-09Updated: 2024-08-07

Phase 2

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome
CompletedNCT03100942
Gilead SciencesSjogren's Syndrome
Start: 2017-05-01End: 2019-10-02Updated: 2020-10-23
Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
CompletedNCT03134222
Gilead SciencesCutaneous Lupus Erythematosus
Start: 2017-05-24End: 2019-12-18Updated: 2020-06-09
Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)
CompletedNCT03285711
Gilead SciencesLupus Membranous Nephropathy
Start: 2017-10-06End: 2020-02-03Updated: 2020-05-18

Related Papers

Monitoramento do Horizonte Tecnológico (MHT) de Inibidores de Janus Quinase (JAKi) para o Tratamento de Lúpus Eritematoso Sistêmico (LES)
Epidemiologia e Serviços de Saúde2025-01-01
The Combination of Lanraplenib, a Selective SYK Inhibitor, and Gilteritinib, a FLT3 Inhibitor, Targets Aberrant Proliferation and Differentiation Blockade in Acute Myeloid Leukemia
Blood2023-11-022 citations
The Novel Profiling Relative Inhibition Simultaneously in Mixtures (PRISM) Platform Identifies Synergistic Activity of Lanraplenib and Ruxolitinib in Hematological Malignancies
Blood2023-11-021 citations
Combined Single Cell Flow Cytometry and Imaging Analyses Reveal Immunomodulatory Effects Exerted By Targeted Phospho-SYK Inhibitors with Elevated Sensitivity in NPM1 Mutated AML
Blood2023-11-02
KB-Lanra 1001: A Phase 1b/2 Study of Safety, PK, PD, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib in Combination with the FLT3 Inhibitor Gilteritinib in FLT3-Mutated R/R AML
Blood2023-11-02
PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML
HemaSphere2023-08-011 citations
Responses in patients with AML and treated with entospletinib monotherapy.
Journal of Clinical Oncology2023-06-011 citations
A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients
Trials2023-02-159 citations
SYK Inhibitors, Entospletinib and Lanraplenib, Show Potent Anti-Leukemic Activity in Combination with Targeted Agents
Blood2022-11-152 citations
P428: SYK INHIBITION DRIVES DEEP RESPONSES IN A BIOMARKER GUIDED SUBSET OF AML ALONE AND IN RATIONAL COMBINATIONS
HemaSphere2022-06-01
P392: PHARMACOLOGICAL INHIBITION OF SYK CONFERS ANTI-PROLIFERATIVE AND NOVEL ANTI-TUMOR IMMUNE RESPONSES IN AML
HemaSphere2022-06-01
Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: a randomized, phase 2, double-blind, placebo-controlled study
Lara D. Veeken2022-04-0465 citations
Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study
Lara D. Veeken2021-09-0862 citations
Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy
RMD Open2020-12-0141 citations